LIPO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LIPO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-12-11), Lipella Pharmaceuticals's share price is $3.02. Lipella Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.93. Hence, Lipella Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Lipella Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:
Lipella Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Sep. 2024 was $-0.58. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.93.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -371.80% per year.
During the past 4 years, Lipella Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was -371.80% per year. The lowest was -371.80% per year. And the median was -371.80% per year.
The historical data trend for Lipella Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipella Pharmaceuticals Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Price-to-Operating-Cash-Flow | - | - | - | - |
Lipella Pharmaceuticals Quarterly Data | ||||||||||||||||
Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Lipella Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Lipella Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
Lipella Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
= | 3.02 | / | -3.933 | |
= |
Lipella Pharmaceuticals's Share Price of today is $3.02.
Lipella Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.93.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Price-to-Operating-Cash-Flow Ratio | = | Market Cap | / | Cash Flow from Operations |
Thank you for viewing the detailed overview of Lipella Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Jonathan H Kaufman | director, 10 percent owner, officer: See Remarks | C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208 |
Lori Birder | director | C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208 |
Daniel R Cohen | director | C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208 |
David S. Battleman | director | C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019 |
Byong Kim | director | C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208 |
Ryan Pruchnic | director | C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208 |
Douglas Johnston | officer: Chief Financial Officer | C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208 |
Michael B Chancellor | director, 10 percent owner, officer: Chief Medical Officer | C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208 |
Naoki Yoshimura | director | C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208 |
From GuruFocus
By Marketwired • 05-21-2024
By PRNewswire • 09-21-2023
By Marketwired • 05-29-2024
By GlobeNewswire • 08-22-2024
By GlobeNewswire • 11-21-2024
By Marketwired • 08-21-2024
By PRNewswire • 10-20-2023
By Marketwired • 08-12-2024
By Marketwired • 07-29-2024
By Marketwired • 10-29-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.